SINGAPORE, 23 April 2026 –
Platform Use Cases: Sustainability Reporting, GHG Calculations, Supplier Engagement
“ESGpedia is a scalable and efficient ESG reporting platform that has been instrumental in advancing our sustainability journey. It enhances our reporting capabilities, particularly in ESG report generation and emissions calculations, supporting us in optimising capital allocations while ensuring high-quality, automated reporting.”
– Jennifer Ribultan, Internal Control Manager, Compliance Officer, Sustainability Lead, Taisho Pharmaceuticals Philippines
Taisho Pharmaceuticals at the Forefront of Sustainability in the Philippines
Taisho Pharmaceuticals Philippines is a wholly owned subsidiary of Taisho Pharmaceutical, a pharmaceutical leader with subsidiaries and networks across America, Europe, and Asia, focused on delivering high-quality pharmaceuticals and health products.
Operating in the Philippines, Taisho Pharmaceuticals manufactures, imports, distributes, and manages pharmaceuticals and energy drinks, leveraging the country’s strategic position as one of Southeast Asia’s largest pharmaceutical markets, which generated nearly $2 billion in revenue in 2025. With the pharmaceutical and healthcare industries contributing approximately 5% of global carbon emissions, the Philippines is uniquely positioned to shape sustainability practices across the sector.
As the Philippines moves towards mandatory sustainability reporting for listed companies, reporting requirements are increasingly cascading across value chains. Non-listed entities like Taisho Pharmaceuticals are experiencing trickle-down implications, with growing pressure from corporate customers, partners, and stakeholders to demonstrate credible sustainability performance.
In this landscape, businesses are recognising sustainability as a strategic advantage, strengthening competitiveness, enhancing stakeholder trust, and positioning themselves ahead of increasing market and regulatory expectations.
Building on this momentum, Taisho Pharmaceuticals is actively driving ESG initiatives within its operations and supply chains, setting a benchmark for the industry. To support these efforts, the company adopted ESGpedia’s ESG reporting platform, enabling enhanced sustainability reporting, robust carbon accounting, and streamlined supplier engagement.
Laying the Groundwork: Early ESG Challenges
With the goal of benchmarking its sustainability practices and performance against global standards, Taisho Pharmaceuticals pursued an EcoVadis assessment in 2022 to obtain an independent, third-party rating.
During the process, key hurdles became apparent. Like many companies, Taisho faced limited in-house sustainability expertise to determine what metrics to track, as well as insufficient infrastructure to effectively manage and report ESG performance. Engaging external consultants for guidance also posed budget constraints, making it difficult to develop a robust ESG report efficiently.
“We did not have in-house expertise to accurately measure key metrics such as carbon emissions or to determine the most appropriate standards aligned with our company size and sustainability maturity.”
– Jennifer Ribultan, Internal Control Manager, Compliance Officer, Sustainability Lead, Taisho Pharmaceuticals Philippines
Implementing digital solutions to navigate sustainability hurdles
Having connected at an engagement organised by the Global Compact Network Philippines, Taisho Pharmaceuticals partnered with ESGpedia to advance on their sustainability reporting journey.
“The ESGpedia team provided a practical and scalable digital solution aligned with our needs and available resources. At that point, we recognised that ESGpedia was the right ESG solution partner to support our sustainability journey.”
– Jennifer Ribultan, Internal Control Manager, Compliance Officer, Sustainability Lead, Taisho Pharmaceuticals Philippines
Aligning Sustainability Reporting with GRI Standards
With ESGpedia’s guidance and proactive advisory from experienced sustainability and data experts, Taisho Pharmaceuticals identified the ESG topics most material and relevant to its business, providing a clear starting point to collect and track the essential ESG metrics.
This enabled the team to efficiently complete Global Reporting Initiative (GRI)-aligned questionnaires, further simplified by built-in guidance notes on the platform.
“The platform has a structured approach with pre-aligned GRI questionnaires, providing clear guidance without requiring extensive in-house technical expertise.”
– Jennifer Ribultan, Internal Control Manager, Compliance Officer, Sustainability Lead, Taisho Pharmaceuticals Philippines
Leveraging ESGpedia’s ESG reporting platform, Taisho effectively generated their audit-ready, GRI-aligned FY2023 and FY2024 Sustainability Reports, shifting reliance away from manual processes and costly, lengthy consultancy services, while ensuring compliance, credibility, and accuracy.
Real-time dashboards and analytics gave the company clear visibility into its ESG performance and progress against targets, delivering actionable ESG insights to strengthen decision-making.
Advancing Digital Carbon Management and Supply Chain Transparency
Taisho Pharmaceuticals established a robust foundation in Scope 1 and 2 emissions reporting, leveraging ESGpedia’s Carbon Calculator to systematically track and analyse the company’s carbon footprint and key emissions drivers.
To strengthen comprehensive sustainability disclosures and advance its supply chain decarbonisation strategy, Taisho Pharmaceuticals leveraged ESGpedia’s Supply Chain ESG module to implement a customised Supplier Engagement questionnaire, so as to actively engage its suppliers for enhanced visibility into value chain and Scope 3 emissions.
End-to-end Access to Sustainability Expert Support: Guided Third-Party Verification
Accelerating Taisho Pharmaceuticals towards ESG excellence in the Philippines
The implementation of ESGpedia’s platform for Sustainability Reporting, Carbon Accounting, and Supplier Engagement has significantly advanced Taisho Pharmaceuticals’ ESG progress and performance, reinforcing the company’s position as a sustainability leader in the Philippine Pharmaceutical market.
Key milestone achievements from the adoption of ESGpedia include:
- Enhanced Sustainability and Carbon Disclosures – Digital tools and access to expert support have enabled Taisho Pharmaceuticals to strengthen its disclosure, compliance, and climate resilience capabilities, so as to better navigate growing reporting pressures in the Philippines and ASEAN market.
- Improved reputation and greater attractiveness to investors through the generation of GRI-aligned Sustainability Reports and the EcoVadis Gold Medal – Taisho Pharmaceuticals doubled its reporting theme score and earned a prestigious Gold Medal in the latest EcoVadis Sustainability Assessment. The distinction places the company in the 96th percentile globally and within the top 2% of companies in its industry, strengthening stakeholder and investor confidence.
- Enhanced supplier engagement and value chain sustainability – Taisho Pharmaceuticals streamlined active engagement with its suppliers, facilitating more structured data collection and value chain emissions tracking, laying the groundwork for more transparent, robust sustainable procurement strategies and further decarbonisation opportunities.
- Heightened business competitiveness – ESGpedia supported Taisho Pharmaceuticals in translating sustainability progress and data insights into measurable business outcomes, helping the company better meet rising demand for responsible products and craft enhanced ESG initiatives.
“While profitability remains a key priority, Taisho Pharmaceutical’s impact on the environment and society is increasingly recognised as a critical driver of long-term, sustainable value creation,” Ms Ribultan explained.
“ESGpedia has proven to be a valuable partner, helping us track and showcase our sustainability progress while providing real-time insights that allow us to adjust targets and align strategies effectively.”
Sustaining Growth through Digitalised ESG Transformation
As sustainability expectations continue to rise, driven by regulatory requirements and evolving consumer demands, Taisho Pharmaceuticals recognises the need to continually adapt its operating model to remain competitive.
Moving forward, Taisho Pharmaceuticals remains steadfast in its commitment to sustainability, embedding responsible practices across its operations and supply chain while continuing to deliver high-quality products.
By leveraging ESGpedia’s one-stop digital platform and sustainability expertise, the pharmaceutical leader aims to further strengthen its ESG performance, enhance transparency, and scale impactful, data-driven sustainability initiatives across the Philippines and beyond.
